Tune in to this health care podcast with drug affordability expert Dr. Bruce Rector as he discusses how to leverage innovation incentives to ensure that the right drugs are developed. Dr. Rector will further discuss the different categories of incentives (push and pull incentives) typically offered […]
Watch Dr. Goodman Talk High Costs for Rare Diseases
The American Journal of Managed Care recently caught up with Dr. Cliff Goodman, senior vice president and director of the Center for Comparative Effectiveness Research, and discussed how decision makers can best assess value as high-cost treatments hit the market. "The emergence and proliferation, […]
FDA Commissioner Targets Orphan Drug Loopholes
Food and Drug Administration Commissioner Scott Gottlieb says he will put and end to any "gaming" of loopholes in the Orphan Drug Act. He's set his crosshairs first on a loophole regarding orphan drug designation. Click here to read more on pharmaphorum.com […]
Orphan Drug Act Distress: A Glimpse at Both Sides
The 1983 Orphan Drug Act led to increased availability for drugs used to treat rare diseases, but prices and consumer allegations about the sway of pharmaceutical companies in United States law have created a maelstrom of controversy about the legislation. Dr. Krishna Patel in Managed Care offered […]
Download: Focus on Rare Diseases
Rare diseases, or diseases affecting fewer than 200,000 people in the United States, have been a focus of drug development for decades, however, according to Rafal Kokolus, senior engagement manager, inVentiv Health Consulting, the rare disease market has now passed a tipping point. Find out more […]
What Does The Future Hold For High-Priced Orphan Drugs – A Payer Perspective
In this recent webinar, What Do Payers Think The Future Holds For Orphan Drugs, interviews with payers tell how they think the orphan drug market will evolve in terms of pricing, reimbursement and market access, and what manufacturers should consider in their orphan drug development strategy. A […]
